Doctors delivery gene-therapy products directly to the heart.  (Bryan Christie, Cardium Therapeutics)

LOS ANGELES –   As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines.

The effort, industry executives told Reuters, is being led by firms developing...

Read the full story